Volume 22, Number 11—November 2016
Research
Risk Factors for Middle East Respiratory Syndrome Coronavirus Infection among Healthcare Personnel
Table 1
Symptom | Seropositive, no./No.† (%) | Seronegative, no./No.† (%) | p value |
---|---|---|---|
Muscle pain | 13/20 (65.0) | 66/260 (25.4) | 0.0001 |
Fever | 12/19 (63.2) | 42/258 (16.3) | <0.0001 |
Dry cough | 11/20 (55.0) | 80/262 (30.5) | 0.02 |
Headache | 11/20 (55.0) | 80/262 (30.5) | 0.02 |
Diarrhea | 7/20 (35.0) | 21/262 (8.0) | 0.0001 |
Nausea | 7/20 (35.0) | 18/262 (6.9) | <0.0001 |
Shortness of breath | 7/20 (35.0) | 32/261 (12.3) | 0.005 |
Runny nose | 6/19 (31.6) | 92/263 (35.0) | 0.76 |
Chills | 6/20 (30.0) | 23/261 (8.8) | 0.003 |
Sore throat | 5/20 (25.0) | 118/263 (44.9) | 0.08 |
Vomiting | 4/20 (20.0) | 10/262 (3.8) | 0.01 |
Productive cough | 3/18 (16.7) | 39/263 (14.8) | 0.74 |
Rash | 1/20 (5.0) | 4/259 (1.5) | 0.26 |
None | 3/20(15.0) | 94/263 (35.7) | 0.019 |
*MERS-CoV, Middle East respiratory syndrome coronavirus.
†Denominator is the number of healthcare personnel who responded to the question.
1These authors contributed equally to this article.
Page created: October 18, 2016
Page updated: October 18, 2016
Page reviewed: October 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.